A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

BACKGROUND: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a patient’s immune system against their tumor and work synergistically with immunotherapy agains...

Descripción completa

Detalles Bibliográficos
Autores principales: Vreeland, Timothy J., Clifton, Guy T., Hale, Diane F., Chick, Robert C., Hickerson, Annelies T., Cindass, Jessica L., Adams, Alexandra M., Bohan, Phillip M. Kemp, Andtbacka, Robert H. I., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Terando, Alicia M., Wagner, Thomas, Peoples, George E., Faries, Mark B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Melanoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914039/
https://www.ncbi.nlm.nih.gov/pubmed/33641012
http://dx.doi.org/10.1245/s10434-021-09709-1

Ejemplares similares